3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
92
Polycystic Ovary Syndrome
10
Neoplasm Metastasis
7
Carcinoma, Ductal, Breast
5
Infertility
4
Carcinoma, Lobular
4
Osteoporosis
3
Neoplasms, Hormone-Dependent
3
Neoplasms
3
Breast Neoplasms, Male
3
Advanced Breast Cancer
3
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Carcinoma In Situ
2
Bone Diseases, Metabolic
2
Unilateral Breast Neoplasms
1
Recurrence
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Obesity
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Infertility, Female
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
HR+/HER2- Breast Cancer
1
HER2+ Breast Cancer
1
Interventions
Carboplatin
8
Paclitaxel
7
Hyperthermic Intraperitoneal Chemotherapy
7
Bevacizumab
4
liposomal doxorubicin
3
Gemcitabine
3
Oxaliplatin
2
Neoadjuvant Therapy
2
relacorilant
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
olaparib
1
nintedanib
1
lobaplatin
1
lanreotide
1
epothilone B
1
atezolizumab
1
Trabectedin
1
Topotecan
1
Therapeutics
1
Surgical Procedures, Operative
1
Saline Solution
1
Leucovorin
1
Letrozole
1
Laparotomy
1
Laparoscopy
1
LAIF 900
1
Hypericum extract LI 160
1
Glucose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
Letrozole
×
Clear all
NCT04111978
2025-09-29
MATAO
Swiss GO Trial Group
Phase 3
Recruiting
540 enrolled